SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                         Date of Report: March 11, 2009
                        (Date of earliest event reported)

                                VASOMEDICAL, INC.
             (Exact name of registrant as specified in its charter)


   Delaware                        0-18105                    11-2871434
--------------------------------------------------------------------------------
State or other                   (Commission                (IRS Employer
jurisdiction of                  File Number)               Identification
incorporation)                                                  Number)


 180 Linden Avenue, Westbury, New York                           11590
--------------------------------------                       --------------
(Address of principal executive offices)                       (Zip Code)



Registrant's telephone number including area code            (516) 997-4600
                                                             --------------

                                 Not applicable
                                 --------------
          (Former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement  communications  pursuant to Rule 13e-4c under the Exchange
Act (17 CFR 240.13e-4c)


Item 5.02  Departure of Directors or Certain  Officers;  Election of  Directors;
           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

     (c) On March  11,  2009,  David  Tarachand  Singh was  appointed  as  Chief
Financial Officer, to serve at the pleasure of the Board of Directors. Mr. Singh
has been employed by the Company  since January 2008 and as Chief  Accountant of
the Company since October 2008.  Mr. Singh was Director of Cost  Accounting  for
Del  Laboratories,  Inc. from August 2005 to December  2007.  From March 1991 to
August 1999 he was Cost  Accounting  Manager and from  September  1999 to August
2005 he was Financial  Operations Manager, of George Weston Bakeries.  Mr. Singh
holds an MBA in general  management  from Dowling College and a BA in accounting
from Queens College.

     Mr. Singh's compensation is at the annual rate of $120,000.



                                   SIGNATURES

     Pursuant to the  requirements  of the  Securities  Exchange Act of 1934, as
amended,  the  Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

                                       VASOMEDICAL, INC.


                                       By: /s/ Jun Ma
                                           -------------------------------------
                                           Jun Ma
                                           President and Chief Executive Officer

Dated:   March 13, 2009